Lars H. Nordenmark

Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

Richard Russell, Latifa Chachi, J. Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 133 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma

Lars H. Nordenmark, Åsa Hellqvist, Claire Emson et al. · NEJM Evidence · 2023 · 101 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Relationship between Emphysema Progression at CT and Mortality in Ever-Smokers: Results from the COPDGene and ECLIPSE Cohorts

Samuel Y. Ash, Raúl San Jośe Estépar, Sean B. Fain et al. · Radiology · 2021 · 60 citations · Full text

Medicine, Chronic Disease Prevention, Clinical Epidemiology +16

A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4

Dave Singh, Patricia Guller, Fred Reid et al. · European Respiratory Journal · 2025 · 48 citations

Medicine, Immunology, Pharmacotherapy +17

Optimal surface segmentation using flow lines to quantify airway abnormalities in chronic obstructive pulmonary disease

Jens Petersen, Mads Nielsen, Pechin Lo et al. · Medical Image Analysis · 2014 · 35 citations

Medicine, Clinical Sciences, Biomedical Imaging +15